NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $6.70 +0.14 (+2.13%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$6.77 +0.07 (+1.00%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$6.33▼$6.8450-Day Range$5.65▼$16.0352-Week Range$4.93▼$16.45Volume513,518 shsAverage Volume685,569 shsMarket Capitalization$260.09 millionP/E RatioN/ADividend YieldN/APrice Target$18.25Consensus RatingModerate Buy Company Overview Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 108th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingEntrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $18.25, representing about 172.4% upside from its current price of $6.70.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.12) to ($3.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.84% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 5.48.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 17.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.58 News SentimentEntrada Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for TRDA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold 3,890.11% more of their company's stock than they have bought. Specifically, they have bought $29,300.00 in company stock and sold $1,169,103.00 in company stock.Percentage Held by Insiders9.49% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 26 at 5:33 PM | globenewswire.comBernhardt Zeiher Buys 5,000 Shares of Entrada Therapeutics (NASDAQ:TRDA) StockMay 22, 2026 | insidertrades.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 21, 2026 | prnewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 21, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAMay 19, 2026 | globenewswire.comINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCMay 18, 2026 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) COO Sells $229,950.00 in StockMay 5, 2026 | insidertrades.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $10.28 at the beginning of 2026. Since then, TRDA stock has decreased by 34.8% and is now trading at $6.70. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) released its earnings results on Thursday, May, 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.11. The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative trailing twelve-month return on equity of 51.22%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Thursday, October 28th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. Who are Entrada Therapeutics' major shareholders? Top institutional shareholders of Entrada Therapeutics include Dimensional Fund Advisors LP (0.84%), Renaissance Technologies LLC (0.52%), Bank of New York Mellon Corp (0.20%) and Quantinno Capital Management LP (0.18%). Insiders that own company stock include Bros Advisors Lp Baker, Bioventures 2018 LP Mpm, Kush Parmar, Ventures V LP 5Am, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth and Peter S Kim. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/07/2026Today5/26/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, TRDA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$18.25 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+172.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.75 million Net Margins-2,895.05% Pretax Margin-2,878.28% Return on Equity-51.22% Return on Assets-42.20% Debt Debt-to-Equity RatioN/A Current Ratio13.90 Quick Ratio13.90 Sales & Book Value Annual Sales$25.42 million Price / Sales10.23 Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book0.96Miscellaneous Outstanding Shares38,820,000Free Float35,137,000Market Cap$260.09 million OptionableOptionable Beta-0.09 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:TRDA) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRDA Stock Alerts